June 2024 SCRI Release Copied

Trials and Trial Regimen Updates

Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens. For
questions about these trials and regimens, please contact SCRI.DLEMRAnalysts@scri.com.

New Build Complete

Study Number	Notes for New Build
24050	USOR 24050 Bridging Therapy (Optional) Dexamethasone or Corticosteroid Q7D USOR 24050 KITE-363 D0-7 USOR 24050 KITE-753 D0-7 USOR 24050 Lymphodepletion Cyclophosphamide D-5, -4, -3 + Fludarabine D-5, -4, -3

Additional Study Updates

Study Number	Updated Reference Information	Updated Regimen Instructions	Other Changes
22083	X	X	Daily dosing days for Sch A changed to D2-8 (from D1-8) Administration instructions updated for Sch A&B Change in amount of “recon soln units” from 0 to 3 million in InvestMedDispense/ InvestMedSelfAdmin instructions
23078	X		Premedication/post-med info added for IRR management. Handling of study drug changed to align with pharmacy instructions Sec 9.1.2
22331	X
21353	X